ERBB2 and cervical carcinoma: In another open-label, multicenter, phase II DESTINY-PanTumor01 study (NCT04639219), patients with solid tumors harboring specific HER2-activating mutations were treated with T-DXd, demonstrating an ORR of 66.7% in cervical cancer patients (Li et al., 2023).